RAD6: a new target to overcome platinum resistance in ovarian cancer?

Ovarian cancer (OC) is a deadly disease, representing the fifth leading cause of cancer death worldwide. In such a context, the major barrier to improve OC survival is resistance to chemotherapy, including platinum. Indeed, the majority of OC patients respond to initial therapy with tumor cytoreductive surgery and platinum-based chemotherapy, but approximately 70% of advanced stage patients will develop tumor recurrence and eventually succumb to recurrent disease, typically characterized by multiple drug resistance (1).